Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TKPHF) EPS (Weighted Average and Diluted) (2017 - 2025)

Historic EPS (Weighted Average and Diluted) for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to $767.0 million.

  • Takeda Pharmaceutical's EPS (Weighted Average and Diluted) fell 1077.59% to $767.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $767.0 million, marking a year-over-year decrease of 1077.59%. This contributed to the annual value of $1.6 billion for FY2025, which is 25396605121210.96% up from last year.
  • Takeda Pharmaceutical's EPS (Weighted Average and Diluted) amounted to $767.0 million in Q4 2025, which was down 1077.59% from $9.9 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's EPS (Weighted Average and Diluted) ranged from a high of $9.9 billion in Q3 2025 and a low of -$77.9 million during Q1 2022
  • Over the past 5 years, Takeda Pharmaceutical's median EPS (Weighted Average and Diluted) value was $1.4 billion (recorded in 2023), while the average stood at $2.3 billion.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 10944.01% in 2022, then surged by 1253621.02% in 2025.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's EPS (Weighted Average and Diluted) stood at $377.5 million in 2021, then surged by 72.77% to $652.2 million in 2022, then soared by 161.99% to $1.7 billion in 2023, then crashed by 49.69% to $859.6 million in 2024, then decreased by 10.78% to $767.0 million in 2025.
  • Its EPS (Weighted Average and Diluted) stands at $767.0 million for Q4 2025, versus $9.9 billion for Q3 2025 and $2.7 billion for Q2 2025.